␤-Lactamase gene promoters of 45 clinical Klebsiella oxytoca isolates resistant to ␤-lactams and exhibiting ␤-lactamase hyperproduction differed from those in 26 susceptible strains. Direct sequencing revealed one mutation in either the ؊10 or ؊35 conserved sequences: a G-to-A transition of the fifth base (67%) or a G-to-T transversion of the first base of the ؊10 sequence (27%) or a T-to-A transversion in the fourth base in the ؊35 sequence (4%). One strain carried both the ؊10 transition and the ؊35 transversion.
Klebsiella oxytoca produces small amounts of a chromosomally encoded ␤-lactamase. Overproduction of this ␤-lactamase causes resistance to penicillins, narrow-spectrum cephalosporins, ceftriaxone, and aztreonam (5); about 8 to 10% of K. oxytoca strains overproduce this ␤-lactamase (3, 11, (14) (15) (16) . Overproduction can result from a mutation in the promoter of the ␤-lactamase gene. In aztreonam-resistant mutants obtained in vitro, one of two different mutations was observed in the Ϫ10 consensus sequence of the promoter (6) . Recently, a second type of ␤-lactamase gene (bla OXY-2 ) with a high degree of nucleotide identity (87.3%) was described for K. oxytoca (7) . Several strains carrying the bla OXY-2 gene also present the characteristic pattern of resistance (to broad-spectrum cephalosporins and monobactams) observed for K. oxytoca strains carrying bla .
In this study, we investigated whether aztreonam-resistant mutants selected in vitro from strains harboring bla OXY-2 carried promoter mutations. In this work, we also report the characterization of 71 clinical strains susceptible and resistant to ␤-lactams harboring one or the other of the bla OXY genes. ␤-Lactam susceptibility, ␤-lactamase activity, and promoter sequences were determined for these strains. Our study demonstrates that mutations were present in the promoters of the resistant strains.
In vitro selection of resistant strains. Mutants were selected in vitro to verify that the ␤-lactamase OXY-2 could be overproduced following mutations in the promoter. K. oxytoca SL902 and SL911 were isolated from St.-Louis Hospital (Paris, France) in 1990 and 1991 respectively. K. oxytoca mutants resistant to aztreonam were selected from these two susceptible strains on Mueller-Hinton agar containing 1 g of aztreonam per ml as described previously (5) . One mutant (SL9111) was obtained from strain SL911 (frequency, 10 Ϫ10 per viable cell), and two mutants (SL9021 and SL9022) were obtained from strain SL902 (frequency, 2 ϫ 10 Ϫ10 per viable cell). The mutation frequencies were similar to that observed for the bla OXY-1 mutant (6). Mutants and parental strains were analyzed by the API 20E and 50CHE systems (bioMérieux). Isoelectric points of in vitro mutants were identical to that of their parental strain, i.e., 5.2 for strain SL911 and its mutant and 6.4 for strain SL902 and its mutants.
Susceptibility testing. K. oxytoca strains were recovered from hospitals in the following countries: France (n ϭ 27), Germany (n ϭ 10), Spain (n ϭ 6), Switzerland (n ϭ 14), United Kingdom (n ϭ 6), and the United States (n ϭ 8). They were identified with the API 20E system (bioMérieux) and by two carbon substrate assimilation tests (histamine and ethanolamine) as described previously (12) . The type of the ␤-lactamase gene (bla OXY-1 or bla OXY-2 ) in each of these isolates was previously determined by colony hybridization (7) . The susceptibilities to ␤-lactams of the 71 K. oxytoca strains were tested by a disk diffusion method with Mueller-Hinton agar (4). The susceptibility patterns clearly fell into two groups FIG. 1. SDS-PAGE of proteins released by osmotic shock. Volumes of shock fluid equivalent to 40 g of protein were loaded. Lanes: 1, SL7811; 2, SL7812; 3, SL781; 4, SL901; 5, SL9011; 6, SL9012; 7, standard protein size markers; 8, SL902; 9, SL9021; 10, SL9022; 11, SL911; 12, SL9111. The ␤-lactamase protein is indicated by the arrow on the right.
( Table 1 ): the first included the 26 strains resistant to penicillins (amoxicillin and ticarcillin) and susceptible to the cephalosporins examined; the second included 45 strains resistant to penicillins, narrow-spectrum cephalosporins (cephalothin), cefuroxime, and aztreonam. The susceptibility patterns of in vitro mutants and the resistant clinical strains harboring either bla OXY-1 or bla OXY-2 were indistinguishable.
␤-Lactamase assays. The strains resistant to ␤-lactams, including cefuroxime and aztreonam, were tested for overproduction of their ␤-lactamase by determination of ␤-lactamase activity by the iodometric method and estimation, on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), of the amount of ␤-lactamase produced by osmotic shock. An overnight culture was diluted 100-fold in 50 ml of LuriaBertani broth. After 3 h of incubation at 37ЊC, 20 ml of the culture was centrifuged and the pellet was sonicated as previously described (5) to obtain crude extract. ␤-Lactamase activity in this crude extract was measured by a quantitative iodometric method with benzylpenicillin as the substrate (13) . The remaining 30 ml of culture was used for osmotic shock by a procedure previously described (1). After protein denaturation, shock fluid containing 40 g of protein was loaded onto a polyacrylamide gel (12.5%) in the presence of SDS. ␤-Lactamase amounts were estimated after staining with Coomassie blue.
The level of ␤-lactamase activity estimated by the iodometric method was higher in the 45 resistant strains (3,539 Ϯ 2,132 mU of ␤-lactamase per mg of protein) than that in the 26 susceptible strains (24.2 Ϯ 10.6) (Comparison of the average values of the two groups by the Student-Fisher t test, P Ͻ 0.001) ( Table 2) .
␤-Lactamase enzyme was obtained by osmotic shock of all the susceptible and resistant strains and migrated with a molecular mass of 29.0 Ϯ 0.5 kDa as observed by Arakawa et al. (2) (Fig. 1) . The susceptible strains SL781 and SL901 and their respective overproducing mutants SL7811, SL7812, SL9011, and SL9012 carry the bla OXY-1 gene (6). The previously described susceptible strains SL911 and SL902 (7) and their respective mutants carry the bla OXY-2 gene. The susceptible strains produced small quantities of ␤-lactamase. The mutants obtained in vitro produced large amounts of ␤-lactamase (Fig.  1) . Similarly, the 26 susceptible clinical strains of K. oxytoca produced small amounts of ␤-lactamase whereas the 45 resistant strains produced large amounts (data not shown).
Promoter sequencing. Primers used to amplify the ␤-lactamase promoter were primer Q, 5Ј-d[TTC ACA AAG CGC TCG GCA AT]-3Ј and primer R, 5Ј-d[CTT TAC TGG TGC TGC ACA TG]-3Ј. The sequences of PCR products were determined directly with the T7 sequencing kit (Pharmacia).
One of two different point mutations was identified in the in vitro mutant promoters (Table 3) : a transversion (G3T) of the first base of the Ϫ10 consensus sequence (SL9021) and a transition (G3A) of the fifth base (in the other two mutants, SL9111 and SL9022). The three mutants carried the same mutations as those previously reported for bla OXY-1 (6) .
The promoter sequences of ␤-lactamase genes from the 71 clinical strains were sequenced ( Table 2) . As expected, all the 26 susceptible K. oxytoca strains had the same Ϫ10 and Ϫ35 consensus sequences (GATAGT and TTGTCA, respectively). All the resistant strains were mutated in one of the two consensus sequences, more often in the Ϫ10 consensus sequence of the promoter (95% of the resistant strains). The most frequent mutation was the transition (G3A) of the fifth base (60% of the bla OXY-1 and 72% of the bla OXY-2 overproducing strains). The same mutation was similarly frequent among the in vitro mutants (75% of the bla OXY-1 mutants [6] and 66% of the bla OXY-2 mutants). The transversion (G3T) of the first base was less common: 35% for the bla OXY-1 and 20% for the bla OXY-2 clinical resistant strains.
Only two clinical strains (one with bla OXY-1 and one with bla OXY-2 ) presented a mutation in the Ϫ35 consensus sequence: a transversion (T3A) in the fourth base. The same mutation has been described for the ampC ␤-lactamase gene in Escherichia coli. It causes a 22-fold increase in transcription from the promoter (9). This mutation was rare in our series (occurring in 5% of the bla OXY-1 and 4% of the bla OXY-2 resistant strains). Finally both this mutation and the transition (G3A) in the Ϫ10 consensus sequence were found in one strain.
Changes in the Ϫ35 and Ϫ10 regions have strong influences on the promoter strength (10) . In E. coli, the promoter is stronger the closer the sequence is to the consensus (Ϫ35 consensus sequence, TTGACA; Ϫ10 consensus sequence, TATAAT) (8) . All of the mutations reported in this work resulted in greater similarity of the promoter sequence with the consensus E. coli promoter sequence.
Studies of ␤-lactamase activity and aztreonam resistance suggest that the transition in the Ϫ10 consensus sequence seems to give a weaker promoter than does the transversion. We are now testing the strengths of these various promoters with a reporter gene on a promoter-probe plasmid.
